Form 4: Amphastar Pharmaceuticals Executive Rong Zhou Reports Acquisition of Stock Options and Restricted Stock Units

Senior EVP Rong Zhou reports the acquisition of stock options and restricted stock units in Amphastar Pharmaceuticals.

Summary

• Rong Zhou, Senior EVP of Production Center at Amphastar Pharmaceuticals, reported changes in beneficial ownership.
• On March 10, 2025, Zhou acquired 24,692 shares of common stock in the form of restricted stock units (RSUs) and 52,437 stock options.
• The RSUs vest in four equal annual installments starting March 10, 2026.
• The stock options, with an exercise price of $28.41, also vest in four equal annual installments beginning March 10, 2026.
• Following the transaction, Zhou directly owns 140,686 shares of common stock.
• Zhou also indirectly owns 99,668 shares through the Zhou Family Trust and 5,000 shares held by their spouse.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The acquisition of shares and options by an executive is generally a positive sign, indicating confidence in the company's future. However, it's a routine filing and doesn't necessarily indicate a major shift in the company's prospects.

Positives

• The acquisition of stock options and RSUs by a senior executive signals confidence in the company's future performance.
• The vesting schedules for both the RSUs and stock options align the executive's interests with the long-term success of the company.

Future Outlook

The vesting schedules for the RSUs and stock options suggest a long-term commitment from the executive to the company's success.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency regarding the transactions of company insiders. These filings are closely watched by investors to gauge management's sentiment and alignment with shareholder interests.

Comparison to Industry Standards

• Stock option and RSU grants are common forms of executive compensation in the pharmaceutical industry.
• Vesting schedules are typically structured to incentivize long-term performance and retention.
• The specific terms of the grants (e.g., vesting period, exercise price) are generally aligned with industry benchmarks and company-specific performance goals.

Stakeholder Impact

• The reported transactions provide transparency to shareholders regarding executive compensation and ownership.
• The vesting schedules for the RSUs and stock options align the executive's interests with the long-term success of the company, potentially benefiting shareholders.

Key Dates